Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Matching Placebo to Ertugliflozin 5 mg
Matching Placebo to Ertugliflozin 10 mg
Matching Placebo to sitagliptin 100 mg
Ertugliflozin 5 mg
Ertugliflozin 10 mg
Sitagliptin 100 mg
Metformin >= 1500 mg/day
Insulin Glargine Rescue Medication
Glimepiride Rescue Medication
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria:
- Type 2 diabetes mellitus as per American Diabetes Association guidelines
- On metformin monotherapy (>=1500 mg/day) for >=8 weeks with a Visit 1/Screening A1C >=7.5% and <=11.0% (>=58 mmol/mol and <=97 mmol/mol) OR On metformin monotherapy (>=1500 mg/day) for <8 weeks with a Visit 1/Screening A1C >=7.5% and <=11.0% (>=58 mmol/mol and <=97 mmol/mol) OR On metformin monotherapy <1500 mg/day with a Visit 1/Screening A1C >=8.0% and <=11.5% (>=64 mmol/mol and <=102 mmol/mol)
- Body mass index (BMI) >=18.0 kg/m^2
- Male or female not of reproductive potential
- Female of reproductive potential who agrees to remain abstinent from heterosexual activity or to use 2 acceptable combinations of contraception
Exclusion Criteria:
- History of type 1 diabetes mellitus or ketoacidosis
- History of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant
- A known hypersensitivity or intolerance to any sodium glucose co-transporter 2 (SGLT2) inhibitor or sitagliptin
- Has been treated with any of the following agents within 12 weeks of study start or during the pre-randomization period: Insulin of any type (except for short-term use [i.e., <=7 days] during concomitant illness or other stress), other injectable anti-hyperglycemic agents (e.g., pramlintide, exenatide, liraglutide), pioglitazone or rosiglitazone, other SGLT2 inhibitors, alpha glucosidase inhibitors or meglitinides, dipeptidyl-peptidase 4 inhibitor (DPP-4 inhibitor), sulfonylureas (SUs), bromocriptine (Cycloset™), colesevelam (Welchol™), any other antihyperglycemic agents (AHA) with the exception of the protocol-approved agents
- Is on a weight-loss program or weight-loss medication or other medication associated with weight changes and is not weight stable prior to study start
- Has undergone bariatric surgery within the past 12 months or >12 months and is not weight stable prior to study start
- A history of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA) functional class III-IV heart failure within 3 months of study start
- Active, obstructive uropathy or indwelling urinary catheter
- History of malignancy <=5 years prior to study start, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
- A known history of human immunodeficiency virus (HIV)
- A blood dyscrasia or any disorder causing hemolysis or unstable red blood cells, or a clinically important hematological disorder (e.g. aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)
- A medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease
- Any clinically significant malabsorption condition
- Current treatment for hyperthyroidism
- On thyroid replacement therapy and not on a stable dose for at least 6 weeks prior study start
- On a previous clinical study with ertugliflozin
- Estimated glomerular filtration rate (eGFR) (using the 4-variable Modification of Diet in Renal Disease Study Equation (MDRD) equation) <60 mL/min/1.73 m^2
- Serum creatinine >= 1.3 mg/dL (115 µmol/L) for males and >= 1.2 mg/dL (106 µmol/L) for females
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 times upper limit of normal
- Hemoglobin <12 g/dL (120 g/L) for males and <11 g/dL (110 g/L) for females.
- Participated in other studies involving investigational drug(s) 30 days prior to study start
- Surgical procedure within 6 weeks prior to study start or major surgery planned during the trial
- Positive urine pregnancy test
- Pregnant or breast-feeding, or planning to conceive during the trial, including 14 days following the last dose of study medication
- Planning to undergo hormonal therapy in preparation for egg donation during the trial, including 14 days following the last dose of study medication
- Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week or engages in binge drinking
- Donated blood or blood products within 6 weeks of study start
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm Type
Experimental
Experimental
Experimental
Experimental
Active Comparator
Arm Label
Ertugliflozin 5 mg + sitagliptin 100 mg
Ertugliflozin 15 mg + sitagliptin 100 mg
Ertugliflozin 5 mg
Ertugliflozin 15 mg
Sitagliptin 100 mg
Arm Description
Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
Ertugliflozin 5 mg, oral, once daily for 52 weeks
Ertugliflozin, oral, once daily for 52 weeks
Sitagliptin 100 mg, oral, once daily for 52 weeks
Outcomes
Primary Outcome Measures
Change From Baseline in A1C at Week 26: Excluding Rescue Approach
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.
Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.
Secondary Outcome Measures
Change From Baseline in Body Weight at Week 26: Excluding Rescue Approach
This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Excluding Rescue Approach
Blood glucose was measured on a fasting basis after at least a 10-hour fast. This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
Percentage of Participants Achieving a Hemoglobin A1C of <7% (<53 mmol/Mol) (Raw Proportions): Excluding Rescue Approach
A1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
Change From Baseline in Static Beta-Cell Sensitivity to Glucose Index at Week 26; Excluding Rescue Approach
Static beta-cell sensitivity to glucose index (SBCSGI) estimates the ratio of insulin secretion (expressed in pmol/min) related to above-basal glucose concentration (expressed in mmol/L * L) following a meal. Blood samples were collected before and after a standard meal and glucose, insulin, and C-peptide levels were analyzed. The C-peptides minimal model was used to estimate the insulin secretion rate (ISR). Analysis included both non-model-based [including insulinogenic index with C-peptide, glucose area under the curve (AUC)/insulin AUC] and model-based [beta cell function and insulin secretion rate at 9 mM glucose] testing. Analysis was performed with non-linear least squares using the Software Architecture Analysis Method (SAAM) II software. SBCSGI was expressed in units of 10^-9 min^-1. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach
This change from baseline reflects the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
Full Information
NCT ID
NCT02099110
First Posted
March 25, 2014
Last Updated
August 14, 2018
Sponsor
Merck Sharp & Dohme LLC
Collaborators
Pfizer
1. Study Identification
Unique Protocol Identification Number
NCT02099110
Brief Title
Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
Official Title
A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin Compared With Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects With T2DM With Inadequate Glycemic Control on Metformin Monotherapy
Study Type
Interventional
2. Study Status
Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
April 22, 2014 (Actual)
Primary Completion Date
May 26, 2016 (Actual)
Study Completion Date
May 26, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Merck Sharp & Dohme LLC
Collaborators
Pfizer
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a study of co-administration of ertugliflozin (MK-8835/PF-04971729) and sitagliptin given together or alone along with metformin in participants with Type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy. The primary hypothesis of this study is that ertugliflozin 15 mg daily plus sitagliptin 100 mg daily provides greater hemoglobin A1C (A1C)-lowering compared with sitagliptin 100 mg daily alone.
Detailed Description
This study will include a 1-week screening period; an up to 12-week metformin titration/dose stabilization period; a 2-week single-blind placebo run-in period; a 52-week (26-week Phase A and 26-week Phase B) double-blind treatment period and a post-treatment telephone contact 14 days after the last dose of study medication.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
1233 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Ertugliflozin 5 mg + sitagliptin 100 mg
Arm Type
Experimental
Arm Description
Ertugliflozin 5 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
Arm Title
Ertugliflozin 15 mg + sitagliptin 100 mg
Arm Type
Experimental
Arm Description
Ertugliflozin 15 mg + sitagliptin 100 mg, oral, once daily for 52 weeks
Arm Title
Ertugliflozin 5 mg
Arm Type
Experimental
Arm Description
Ertugliflozin 5 mg, oral, once daily for 52 weeks
Arm Title
Ertugliflozin 15 mg
Arm Type
Experimental
Arm Description
Ertugliflozin, oral, once daily for 52 weeks
Arm Title
Sitagliptin 100 mg
Arm Type
Active Comparator
Arm Description
Sitagliptin 100 mg, oral, once daily for 52 weeks
Intervention Type
Drug
Intervention Name(s)
Matching Placebo to Ertugliflozin 5 mg
Intervention Description
Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Intervention Type
Drug
Intervention Name(s)
Matching Placebo to Ertugliflozin 10 mg
Intervention Description
Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Intervention Type
Drug
Intervention Name(s)
Matching Placebo to sitagliptin 100 mg
Intervention Description
Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Intervention Type
Drug
Intervention Name(s)
Ertugliflozin 5 mg
Other Intervention Name(s)
MK-8835, PF-04971729
Intervention Description
Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Intervention Type
Drug
Intervention Name(s)
Ertugliflozin 10 mg
Other Intervention Name(s)
MK-8835, PF-04971729
Intervention Description
Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Intervention Type
Drug
Intervention Name(s)
Sitagliptin 100 mg
Other Intervention Name(s)
JANUVIA®
Intervention Description
Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
Intervention Type
Drug
Intervention Name(s)
Metformin >= 1500 mg/day
Other Intervention Name(s)
Glucophage, Glucophage XR
Intervention Description
Metformin >= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period
Intervention Type
Biological
Intervention Name(s)
Insulin Glargine Rescue Medication
Other Intervention Name(s)
Lantus
Intervention Description
Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion
Intervention Type
Drug
Intervention Name(s)
Glimepiride Rescue Medication
Other Intervention Name(s)
AMARYL
Intervention Description
Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion
Primary Outcome Measure Information:
Title
Change From Baseline in A1C at Week 26: Excluding Rescue Approach
Description
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). This change from baseline reflects the Week 26 A1C minus the Week 0 A1C. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
Time Frame
Baseline and Week 26
Title
Percentage of Participants Who Experienced an Adverse Event (AE): Including Rescue Approach
Description
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.
Time Frame
Up to 54 weeks
Title
Percentage of Participants Who Discontinued Study Treatment Due to an AE: Including Rescue Approach
Description
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Including rescue approach data analysis included data following the initiation of rescue therapy.
Time Frame
Up to 52 weeks
Secondary Outcome Measure Information:
Title
Change From Baseline in Body Weight at Week 26: Excluding Rescue Approach
Description
This change from baseline reflects the Week 26 body weight minus the Week 0 body weight. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
Time Frame
Baseline and Week 26
Title
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26 - Excluding Rescue Approach
Description
Blood glucose was measured on a fasting basis after at least a 10-hour fast. This change from baseline reflects the Week 26 FPG minus the Week 0 FPG. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
Time Frame
Baseline and Week 26
Title
Percentage of Participants Achieving a Hemoglobin A1C of <7% (<53 mmol/Mol) (Raw Proportions): Excluding Rescue Approach
Description
A1C is blood marker used to report average blood glucose levels over a prolonged periods of time and is reported as a percentage (%). Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
Time Frame
Week 26
Title
Change From Baseline in Static Beta-Cell Sensitivity to Glucose Index at Week 26; Excluding Rescue Approach
Description
Static beta-cell sensitivity to glucose index (SBCSGI) estimates the ratio of insulin secretion (expressed in pmol/min) related to above-basal glucose concentration (expressed in mmol/L * L) following a meal. Blood samples were collected before and after a standard meal and glucose, insulin, and C-peptide levels were analyzed. The C-peptides minimal model was used to estimate the insulin secretion rate (ISR). Analysis included both non-model-based [including insulinogenic index with C-peptide, glucose area under the curve (AUC)/insulin AUC] and model-based [beta cell function and insulin secretion rate at 9 mM glucose] testing. Analysis was performed with non-linear least squares using the Software Architecture Analysis Method (SAAM) II software. SBCSGI was expressed in units of 10^-9 min^-1. Excluding rescue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
Time Frame
30 min. before and 0, 15, 30, 60, 90, 120, and 180 minutes following the start of the standard meal at Baseline and Week 26
Title
Change From Baseline in Sitting Systolic Blood Pressure at Week 26: Excluding Rescue Approach
Description
This change from baseline reflects the Week 26 systolic blood pressure minus the Week 0 systolic blood pressure. Excluding recue approach data analysis excluded all data following the initiation of rescue therapy at any time point, in order to avoid the confounding influence of the rescue therapy.
Time Frame
Baseline and Week 26
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Type 2 diabetes mellitus as per American Diabetes Association guidelines
On metformin monotherapy (>=1500 mg/day) for >=8 weeks with a Visit 1/Screening A1C >=7.5% and <=11.0% (>=58 mmol/mol and <=97 mmol/mol) OR On metformin monotherapy (>=1500 mg/day) for <8 weeks with a Visit 1/Screening A1C >=7.5% and <=11.0% (>=58 mmol/mol and <=97 mmol/mol) OR On metformin monotherapy <1500 mg/day with a Visit 1/Screening A1C >=8.0% and <=11.5% (>=64 mmol/mol and <=102 mmol/mol)
Body mass index (BMI) >=18.0 kg/m^2
Male or female not of reproductive potential
Female of reproductive potential who agrees to remain abstinent from heterosexual activity or to use 2 acceptable combinations of contraception
Exclusion Criteria:
History of type 1 diabetes mellitus or ketoacidosis
History of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant
A known hypersensitivity or intolerance to any sodium glucose co-transporter 2 (SGLT2) inhibitor or sitagliptin
Has been treated with any of the following agents within 12 weeks of study start or during the pre-randomization period: Insulin of any type (except for short-term use [i.e., <=7 days] during concomitant illness or other stress), other injectable anti-hyperglycemic agents (e.g., pramlintide, exenatide, liraglutide), pioglitazone or rosiglitazone, other SGLT2 inhibitors, alpha glucosidase inhibitors or meglitinides, dipeptidyl-peptidase 4 inhibitor (DPP-4 inhibitor), sulfonylureas (SUs), bromocriptine (Cycloset™), colesevelam (Welchol™), any other antihyperglycemic agents (AHA) with the exception of the protocol-approved agents
Is on a weight-loss program or weight-loss medication or other medication associated with weight changes and is not weight stable prior to study start
Has undergone bariatric surgery within the past 12 months or >12 months and is not weight stable prior to study start
A history of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA) functional class III-IV heart failure within 3 months of study start
Active, obstructive uropathy or indwelling urinary catheter
History of malignancy <=5 years prior to study start, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
A known history of human immunodeficiency virus (HIV)
A blood dyscrasia or any disorder causing hemolysis or unstable red blood cells, or a clinically important hematological disorder (e.g. aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)
A medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease
Any clinically significant malabsorption condition
Current treatment for hyperthyroidism
On thyroid replacement therapy and not on a stable dose for at least 6 weeks prior study start
On a previous clinical study with ertugliflozin
Estimated glomerular filtration rate (eGFR) (using the 4-variable Modification of Diet in Renal Disease Study Equation (MDRD) equation) <60 mL/min/1.73 m^2
Serum creatinine >= 1.3 mg/dL (115 µmol/L) for males and >= 1.2 mg/dL (106 µmol/L) for females
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2 times upper limit of normal
Hemoglobin <12 g/dL (120 g/L) for males and <11 g/dL (110 g/L) for females.
Participated in other studies involving investigational drug(s) 30 days prior to study start
Surgical procedure within 6 weeks prior to study start or major surgery planned during the trial
Positive urine pregnancy test
Pregnant or breast-feeding, or planning to conceive during the trial, including 14 days following the last dose of study medication
Planning to undergo hormonal therapy in preparation for egg donation during the trial, including 14 days following the last dose of study medication
Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week or engages in binge drinking
Donated blood or blood products within 6 weeks of study start
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Medical Director
Organizational Affiliation
Merck Sharp & Dohme LLC
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
IPD Sharing URL
http://engagezone.msd.com/ds_documentation.php
Citations:
PubMed Identifier
29266675
Citation
Pratley RE, Eldor R, Raji A, Golm G, Huyck SB, Qiu Y, Sunga S, Johnson J, Terra SG, Mancuso JP, Engel SS, Lauring B. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018 May;20(5):1111-1120. doi: 10.1111/dom.13194. Epub 2018 Jan 25.
Results Reference
result
PubMed Identifier
34213819
Citation
Fediuk DJ, Sahasrabudhe V, Dawra VK, Zhou S, Sweeney K. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1297-1306. doi: 10.1002/cpdd.970. Epub 2021 Jul 2.
Results Reference
derived
PubMed Identifier
32700393
Citation
Gallo S, Raji A, Calle RA, Pong A, Meyer C. The effects of ertugliflozin on beta-cell function: Pooled analysis from four phase 3 randomized controlled studies. Diabetes Obes Metab. 2020 Dec;22(12):2267-2275. doi: 10.1111/dom.14149. Epub 2020 Aug 27.
Results Reference
derived
PubMed Identifier
32648108
Citation
Gallo S, Calle RA, Terra SG, Pong A, Tarasenko L, Raji A. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials. Diabetes Ther. 2020 Aug;11(8):1849-1860. doi: 10.1007/s13300-020-00867-1. Epub 2020 Jul 9.
Results Reference
derived
PubMed Identifier
32372382
Citation
Patel S, Hickman A, Frederich R, Johnson S, Huyck S, Mancuso JP, Gantz I, Terra SG. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials. Diabetes Ther. 2020 Jun;11(6):1347-1367. doi: 10.1007/s13300-020-00803-3. Epub 2020 May 5.
Results Reference
derived
PubMed Identifier
32324082
Citation
Liu J, Tarasenko L, Pong A, Huyck S, Wu L, Patel S, Hickman A, Mancuso JP, Gantz I, Terra SG. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Aug;36(8):1277-1284. doi: 10.1080/03007995.2020.1760228. Epub 2020 May 13.
Results Reference
derived
PubMed Identifier
32324065
Citation
Liu J, Tarasenko L, Pong A, Huyck S, Patel S, Hickman A, Mancuso JP, Ellison MC, Gantz I, Terra SG. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020 Jul;36(7):1097-1106. doi: 10.1080/03007995.2020.1760227. Epub 2020 May 13.
Results Reference
derived
PubMed Identifier
31797522
Citation
Liu J, Patel S, Cater NB, Wu L, Huyck S, Terra SG, Hickman A, Darekar A, Pong A, Gantz I. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2020 Apr;22(4):574-582. doi: 10.1111/dom.13931. Epub 2020 Jan 3.
Results Reference
derived
Learn more about this trial
Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
We'll reach out to this number within 24 hrs